iptacopan: Clinical Trials

14 trials of iptacopan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 recruiting, 5 completed, 2 active not recruiting. 14 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 314Recruiting 7, Completed 5, Active not recruiting 2

Follow iptacopan: new trials by email Literature Review of iptacopan trials Research Report on iptacopan

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
iptacopan - Primary Immunoglobulin A Nephropathy (IgAN)
Phase 3RecruitingNovartis Pharmaceuticals312025-11-272026-09-09
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
LNP023 - Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3RecruitingNovartis Pharmaceuticals122025-10-282026-08-07
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Iptacopan, Matching Placebo - Generalized Myasthenia Gravis
Phase 3Active not recruitingNovartis Pharmaceuticals1462024-07-312026-08-12
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Iptacopan - Atypical Hemolytic Uremic Syndrome
Phase 3RecruitingNovartis Pharmaceuticals502024-02-282026-04-29
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Placebo, iptacopan - IC-MPGN
Phase 3RecruitingNovartis Pharmaceuticals1062023-10-022026-07-13
Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
Iptacopan - Paroxysmal Nocturnal Hemoglobinuria
Phase 3CompletedNovartis Pharmaceuticals522023-04-242026-01-13
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
Iptacopan - Atypical Hemolytic Uremic Syndrome
Phase 3CompletedNovartis Pharmaceuticals342022-01-172026-08-07
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
LNP023 - Primary IgA Nephropathy
Phase 3RecruitingNovartis Pharmaceuticals5402021-09-202026-10-05
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Placebo, iptacopan - C3G
Phase 3RecruitingNovartis Pharmaceuticals982021-07-282026-11-05
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
Iptacopan - Paroxysmal Nocturnal Hemoglobinuria
Phase 3Active not recruitingNovartis Pharmaceuticals2082021-07-272026-08-07
Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
Iptacopan (LNP023) - Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3CompletedNovartis Pharmaceuticals402021-07-192024-10-09
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
LNP023, Eculizumab, Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3CompletedNovartis Pharmaceuticals972021-01-252024-10-09
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Placebo, LNP023 - IgA Nephropathy
Phase 3CompletedNovartis Pharmaceuticals5172021-01-252026-11-04
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
LNP023 - C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
Phase 3RecruitingNovartis Pharmaceuticals2252019-10-032026-08-07

Conditions studied

Hemoglobinuria, Paroxysmal (5)  ·  Anemia (4)  ·  Proteinuria (4)  ·  Glomerulonephritis, IGA (3)  ·  Atypical Hemolytic Uremic Syndrome (2)  ·  Thrombotic Microangiopathies (2)  ·  Glomerulonephritis (1)  ·  Glomerulonephritis, Membranoproliferative (1)  ·  Myasthenia Gravis (1)  ·  Renal Insufficiency, Chronic (1)

Sponsors

Novartis Pharmaceuticals (14)

Countries

Germany (12)  ·  Italy (12)  ·  United States (12)  ·  France (11)  ·  Japan (11)  ·  United Kingdom (11)  ·  Brazil (10)  ·  China (10)  ·  Spain (10)  ·  South Korea (9)  ·  Czechia (8)  ·  Netherlands (8)  ·  Turkey (Türkiye) (8)  ·  Argentina (7)  ·  Israel (7)

Results publications

PMID 40694294, PMID 38477987, PMID 40447351, PMID 35675911, PMID 37772889, PMID 37914086, PMID 38299639, PMID 39453772, PMID 41016405, PMID 41661687, PMID 41910396, PMID 42909451

NIH funding

2023 (3), 2018 (1), 2019 (1)